Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 121

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 121
---
 (such as other comprehensive income), and the exception to using general methodology for the interim period tax accounting for year-to-date losses that exceed anticipated losses. The guidance was effective for the Company beginning January 1, 2022, and interim periods in fiscal years beginning January 1, 2023. The implementation of ASU 2019-12 didn’t have material effect on its financial statements and related disclosures.

<div align='center'>F-14</div>

REVIUM RX.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

U.S. dollars in thousands

NOTE 3 – UNAUDITED CONDENSED FINANCIAL STATEMENTS

The accompanying condensed consolidated balance sheet as of September 30, 2024, the condensed consolidated statements of comprehensive loss and the condensed consolidated statements of cash flows for the period commencing July 24, 2024 through September 30, 2024, are unaudited and have been approved for issuance on February 12, 2025.

These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission regarding condensed financial reporting. In management’s opinion, the unaudited condensed consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company’s financial position as of September 30, 2024, as well as its results of operations and cash flows for the period commencing July 24, 2024 through September 30 2024, are not necessarily indicative of the results to be expected for the year ending December 31, 2024

NOTE 4 – ACQUISITION

The Company accounted for the following transaction as a business combination and allocated the purchase consideration to assets acquired and liabilities assumed based on their estimated fair values.

On November 14, 2023, the Company entered into the Stock Exchange Agreement (the “Share Exchange Agreement”) with Predecessor.(formerly known as LipoVac Ltd), an Israeli company (“LipoVation”) and the shareholders of Predecessor pursuant to which the former shareholders of LipoVation have agreed to contribute all of their shareholdings in Predecessor in exchange for the right to receive shares of the Company’s common stock. On July 23, 2024, the transactions contemplated under the Stock Exchange Agreement were closed and as a result Predecessor became